We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Key miRNA Profiling to Boost Company Fortunes in 2012

By LabMedica International staff writers
Posted on 25 Jan 2012
The coming year is set to witness dramatic growth of biotechnology companies specializing in stem cell research and drug development.

One such company is Sistemic Ltd. More...
(Glasgow, United Kingdom), which has planned a GBP 1 million investment program for 2012. A portion of this investment is to be covered by a substantial Scottish Regional Selective Assistance (RSA) grant from Scottish Enterprise.

Sistemic’s activities are currently focused on microRNAs (miRNAs) and miRNA profiling. MicroRNAs are seen as the master controllers of the cell and, as such, Sistemic believes they provide information on the effects within a whole cell or organism rather than an isolated pathway. This systems approach means that the data produced is more indicative of the biology and more informative of actual effect. As a result, Sistemic leverages miRNA based profiling/fingerprinting to provide information rich products to companies worldwide.

Systemic has developed proprietary statistical algorithms that robustly and with a high degree of confidence analyze changes to miRNAs when a cell is perturbed by a stimulus. Together with innovative visualization techniques, Systemic is able to generate a fingerprint of a key set of miRNAs known as “key miRNAs” (kmiRs) that represent these changes accurately.

The Sistemic methodology provides a rigorous yet rapid understanding of the biological changes that occur within a cell. Resulting data, allows companies to make well-informed decisions, in a timely fashion. This enables them to develop their cell (or stem cell) therapy accordingly.

Jim Reid, CEO of Sistemic said, “Securing this support from Scottish Enterprise is a major achievement and shows great support by the Scottish Government for what we are doing. It adds to an already successful year for Sistemic, a year, which has seen us grow sales dramatically and develop our customer base in Europe, USA, Japan, and Australia. We truly have become a global company during 2011 and we look forward to relocating in the first half of 2012 to allow this success and growth to continue. It is always an exciting opportunity to be on the lookout for new employees and we are ideally placed to recruit top talent. This type of grant support is crucial to help grow successful research focused biotech companies such as ours and we will ensure we make the most of it!”

Related Links:
Sistemic Ltd.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.